MCID: RHM027
MIFTS: 62

Rheumatic Disease

Categories: Cardiovascular diseases, Immune diseases

Aliases & Classifications for Rheumatic Disease

Summaries for Rheumatic Disease

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to spondyloarthropathy 1 and palindromic rheumatism, and has symptoms including joint symptom, myalgia and musculoskeletal symptom. An important gene associated with Rheumatic Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and IL-2 Pathway. The drugs Methotrexate and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 32.4 CD40LG CRP HLA-B TNF
2 palindromic rheumatism 32.0 CRP HLA-DRB1 IL1B TNF
3 arthritis 30.5 HLA-DRB1 IFNG IL10 IL1B PTGS2 TNF
4 osteoarthritis 30.4 CRP IL1B PTGS2 TNF
5 rheumatoid arthritis 30.4 CD40LG CRP HLA-B HLA-DRB1 HMGB1 IFNG
6 psoriatic arthritis 30.2 CRP HLA-B HLA-DRB1 IL1B TNF
7 arteries, anomalies of 30.1 CRP IL1B TNF VCAM1
8 joint disorders 30.1 IL1B IL1R1 TNF
9 chikungunya 30.0 CD40LG IL1B TNF
10 cystitis 30.0 CRP PTGS2 TNF
11 synovitis 29.9 CRP IL1B TNF VCAM1
12 hematopoietic stem cell transplantation 29.9 HLA-B IFNG IL10 TNF
13 bronchiolitis obliterans 29.9 IFNG IL10 TNF
14 lupus erythematosus 29.8 APOH CD40LG SSB TNF TRIM21
15 chronic fatigue syndrome 29.8 IL10 IL1B TNF
16 interstitial lung disease 29.8 IFNG IL10 IL1B TNF
17 pneumonia 29.7 CD40LG CRP IL10 IL1B TNF
18 spondylitis 29.7 CD40LG CRP HLA-B TNF
19 vasculitis 29.7 APOH CD40LG CRP TNF VCAM1
20 reactive arthritis 29.7 CRP HLA-B IFNG IL10 TNF
21 leishmaniasis 29.6 HLA-DRB1 IFNG IL10 IL1B TNF
22 demyelinating disease 29.5 CD40LG IFNG IL10 IL1B TNF
23 leprosy 3 29.5 CD40LG IFNG IL10 TNF
24 mumps 29.5 CD40LG HLA-DRB1 IFNG IL2RA
25 bronchiolitis 29.5 CD40LG IFNG IL10 TNF
26 rubella 29.4 CD40LG HLA-B HLA-DRB1 IL10 TNF
27 tetanus 29.3 CD40LG IFNG IL10 IL2RA
28 myocardial infarction 29.3 CD40LG CRP IL10 IL1B PTGS2 TNF
29 uveitis 29.3 HLA-B IFNG IL10 IL1R1 IL2RA TNF
30 chlamydia 29.1 CD40LG CRP IFNG IL10 IL1B TNF
31 mixed connective tissue disease 29.1 CD40LG HLA-DRB1 IFNG IL10 RNPC3 TNF
32 temporal arteritis 29.1 APOH CD40LG CRP HLA-DRB1 IFNG
33 sjogren syndrome 29.0 APOH CENPB SSB TRIM21
34 inflammatory bowel disease 28.6 CRP HLA-B HLA-DRB1 IFNG IL10 IL1B
35 connective tissue disease 28.1 APOH CD40LG CENPB HLA-DRB1 IFNG IL10
36 systemic lupus erythematosus 27.9 APOH CD40LG CRP HLA-DRB1 HMGB1 IFNG
37 enthesopathy 11.2
38 macrophage activation syndrome 11.2
39 rheumatic pulmonary valve disease 11.0
40 tricuspid valve disease 10.9
41 mitral valve disease 10.9
42 juvenile spondyloarthropathy 10.8
43 singleton-merten syndrome 10.8
44 postherpetic neuralgia 10.6 HLA-B HLA-DRB1
45 polyposis, gastric 10.6 IL1B TNF
46 nontuberculous mycobacterial lung disease 10.6 HLA-B HLA-DRB1 TNF
47 alveolar echinococcosis 10.6 HLA-B HLA-DRB1 TNF
48 idiopathic inflammatory myopathy 10.6 HLA-B HLA-DRB1 TRIM21
49 punctate inner choroidopathy 10.6 IL10 TNF
50 geographic tongue 10.6 HLA-B HLA-DRB1 TNF

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


joint symptom, myalgia, musculoskeletal symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

25 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.03 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 10.03 HMGB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.03 IL2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 10.03 APOH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.03 SSB HMGB1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.03 SSB IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.03 APOH IL2RA SSB HMGB1 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.03 IL2RA HMGB1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.03 IL2RA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.03 SSB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.03 IL2RA IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.03 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.03 APOH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.03 SSB IL10
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.03 IL10
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL1B APOH IL2RA CD40LG SSB TNF
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL1B APOH IL2RA CD40LG SSB TNF

MGI Mouse Phenotypes related to Rheumatic Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 PTGS2 CD40LG CENPA CRP TNF IFNG
2 hematopoietic system MP:0005397 9.9 IL2RA PTGS2 CD40LG SSB TNF IFNG
3 immune system MP:0005387 9.73 IL2RA PTGS2 CD40LG SSB CRP TNF
4 mortality/aging MP:0010768 9.47 IL2RA APOH PTGS2 CD40LG SSB CENPA

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 930)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
7
Sulfasalazine Approved Phase 4,Phase 3,Phase 2 599-79-1 5359476 5353980
8
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
9
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
10
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
11
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9004-61-9 53477741 24759
12
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
13
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
14
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 1197-18-8 5526
15
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
16
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2 169590-42-5 2662
17
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1 161796-78-7, 119141-88-7 9579578 4594
18
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 156391 1302
19
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38396-39-3, 2180-92-9 2474
20
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
22
Ropivacaine Approved Phase 4,Phase 3,Phase 2 84057-95-4 175805 71273
23
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
24
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2 51481-61-9 2756
25
Hyoscyamine Approved Phase 4 101-31-5 64692
26
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
27
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
28
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
29
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 202409-33-4 123619
30
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
31
Fluorouracil Approved Phase 4 51-21-8 3385
32
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
33
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 15307-86-5 3033
34
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
35
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
36
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1 50-48-6 2160
37
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2 303-53-7 2895
38
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
39
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
40
Ketorolac Approved Phase 4,Phase 3,Phase 2 74103-06-3, 66635-83-4 3826
41
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
42 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 329-65-7
43
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
44
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
45
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
46
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
47
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
48
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 27203-92-5 33741
49
Tacrolimus Approved, Investigational Phase 4,Phase 3,Early Phase 1 104987-11-3 445643 439492
50
Betamethasone Approved, Vet_approved Phase 4,Phase 3 378-44-9 9782

Interventional clinical trials:

(show top 50) (show all 6056)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Hanyang University Medical Center Arthritis Network Unknown status NCT00418405 Phase 4
3 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
4 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
5 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
6 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
7 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
8 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
9 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
10 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
11 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
12 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
13 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
14 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
15 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
16 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
17 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
18 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
19 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
20 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
21 Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis Unknown status NCT02320500 Phase 4
22 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
23 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
24 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
25 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Unknown status NCT02086474 Phase 4 Hyaluronan;Bupivacaine
26 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
27 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
28 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
29 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
30 Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women Unknown status NCT01926158 Phase 4 Denosumb;Placebo (for denosumab)
31 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
32 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
33 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
34 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
35 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
36 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
37 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
38 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
39 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
40 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
41 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
42 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
43 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
44 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
45 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
46 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
47 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib
48 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
49 A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty Unknown status NCT00138892 Phase 4
50 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

38
Bone, Testes, Heart, Eye, Bone Marrow, Brain, Skin

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 896)
# Title Authors Year
1
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada. ( 29437583 )
2018
2
Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. ( 29363290 )
2018
3
Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. ( 29290190 )
2018
4
Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? ( 29437584 )
2018
5
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. ( 29318514 )
2018
6
Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. ( 29391382 )
2018
7
Neutrophilic urticarial dermatosis: a novel association with poststreptococcal rheumatic disease. ( 29271002 )
2017
8
Causes and consequences of endoplasmic reticulum stress in rheumatic disease. ( 27904144 )
2017
9
Sexual and reproductive health in rheumatic disease. ( 28680137 )
2017
10
Therapy: Rheumatic disease after immune checkpoint inhibitor therapy. ( 28660915 )
2017
11
Re: Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733793 )
2017
12
Post-Chikungunya Rheumatic Disease in a 13-Year-Old Boy. ( 28884916 )
2017
13
Systematic review and meta-analysis of the epidemiology of polyautoimmunity in SjAPgren's syndrome (secondary SjAPgren's syndrome) focusing on autoimmune rheumatic diseases. ( 28927315 )
2017
14
Health-related quality of life of rheumatic disease patients treated in a specialized IPS in Medellin, Colombia. ( 29362597 )
2017
15
Cardiovascular morbidity and mortality in patients with rheumatic disease: hyperuricemia, a forgotten puzzle piece? ( 29058173 )
2017
16
Clinical and ultrasonographic enthesopathy in inflammatory rheumatic diseases : Is MASEI or only calcaneal enthesitis sufficient? ( 29116386 )
2017
17
Robot-Assisted Mitral Valve Repair With Posterior Leaflet Extension for Rheumatic Disease. ( 28085691 )
2017
18
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. ( 28711176 )
2017
19
The Incidence of Atypical Femoral Fractures in Patients with Rheumatic Disease: Yamagata Prefectural Committee of Atypical Femoral Fractures (YamaCAFe) Study. ( 28883214 )
2017
20
Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. ( 28637725 )
2017
21
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 28535894 )
2017
22
Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. ( 28051109 )
2017
23
Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. ( 28245862 )
2017
24
What do young people with rheumatic disease believe to be important to research about their condition? A UK-wide study. ( 28673355 )
2017
25
Socioeconomic burden of pain in rheumatic disease. ( 28967363 )
2017
26
Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733792 )
2017
27
Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. ( 28748510 )
2017
28
Heterotopic ossification (myositis ossificans progressiva): A condition interfering with rheumatic disease. ( 28293462 )
2017
29
Neurological Complications of Rheumatic Disease. ( 28779866 )
2017
30
The complement system as a potential therapeutic target in rheumatic disease. ( 28794515 )
2017
31
Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases. ( 28646351 )
2017
32
Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. ( 28812405 )
2017
33
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28725036 )
2017
34
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28660911 )
2017
35
Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. ( 28583280 )
2017
36
Paediatric rheumatic disease: Multi-pronged approach uncovers sJIA mechanisms. ( 29021570 )
2017
37
Population Genetics and Natural Selection in Rheumatic Disease. ( 28711136 )
2017
38
Paediatric rheumatic disease: Systemic JIA genetically distinct. ( 28077866 )
2017
39
Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. ( 27998507 )
2017
40
Macrophage Activation Syndrome in Paediatric Rheumatic Diseases. ( 28588173 )
2017
41
The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease. ( 27893701 )
2017
42
The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. ( 29164003 )
2017
43
Mortality causes and outcomes in Indigenous populations of Canada, the United States, and Australia with rheumatic disease: A systematic review. ( 28823732 )
2017
44
Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. ( 27803141 )
2017
45
Total Chordal Sparing Mitral Valve Replacement in Rheumatic Disease: A Word of Caution. ( 28633260 )
2017
46
Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. ( 28936564 )
2017
47
Human microbiome, infections, and rheumatic disease. ( 29101674 )
2017
48
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. ( 28535619 )
2017
49
Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease. ( 29061246 )
2017
50
Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFI+ therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabecular bone score. ( 29164001 )
2017

Variations for Rheumatic Disease

Expression for Rheumatic Disease

Search GEO for disease gene expression data for Rheumatic Disease.

Pathways for Rheumatic Disease

Pathways related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CD40LG CRP HLA-B HLA-DRB1 HMGB1 IFNG
2
Show member pathways
13.26 HLA-DRB1 HMGB1 IFNG IL1B IL1R1 IL2RA
3
Show member pathways
13.21 CD40LG HLA-B HLA-DRB1 IFNG IL10 IL1B
4
Show member pathways
12.85 HLA-B HLA-DRB1 IFNG IL1B IL2RA TNF
5
Show member pathways
12.85 CD40LG HLA-B HLA-DRB1 IFNG IL10 IL1B
6
Show member pathways
12.71 CD40LG IFNG IL1B IL1R1 TNF
7
Show member pathways
12.68 CD40LG HLA-DRB1 IFNG IL10 IL2RA TNF
8
Show member pathways
12.62 HLA-DRB1 IFNG IL10 IL1B IL1R1 IL2RA
9
Show member pathways
12.59 HLA-B HLA-DRB1 IFNG TRIM21 VCAM1
10 12.55 CD40LG IFNG IL10 IL1B IL2RA PTGS2
11
Show member pathways
12.49 CD40LG IFNG IL10 IL1B TNF
12 12.48 HLA-B HLA-DRB1 IL1R1 IL2RA TNF VCAM1
13
Show member pathways
12.38 CRP IFNG IL1B PTGS2 TNF
14
Show member pathways
12.36 IFNG IL1B PTGS2 TNF
15 12.33 HLA-B HLA-DRB1 IFNG IL10
16
Show member pathways
12.32 IFNG IL1B IL1R1 PTGS2 TNF
17 12.28 HLA-DRB1 IFNG IL10 IL1B TNF
18
Show member pathways
12.26 HMGB1 IFNG IL1B TNF
19
Show member pathways
12.23 IFNG IL1B IL1R1 TNF
20
Show member pathways
12.22 CD40LG HLA-DRB1 IFNG IL10 IL1B PTGS2
21
Show member pathways
12.21 HLA-B IFNG IL10 IL1B TNF
22 12.16 CD40LG HLA-B HLA-DRB1 VCAM1
23 12.15 IFNG IL1B IL1R1 TNF VCAM1
24 12.1 IFNG IL1B IL1R1 TNF
25 12.07 IFNG IL1B IL1R1 PTGS2 TNF
26 12.05 IFNG IL10 IL2RA TNF
27 12.04 IL10 IL1B PTGS2 TNF VCAM1
28
Show member pathways
12.03 HLA-DRB1 IFNG IL1B IL1R1 IL2RA
29 12.01 IL1B PTGS2 TNF VCAM1
30
Show member pathways
11.98